Clinical Trial of Hydroquinone Versus Miconazol in Melasma
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Melasma is an acquired discoloration of the skin characterized by brown colour changes
commonly on the face.The duration of this double-blind clinical trial will be 12 weeks. The
control group will receive treatment with topical Hydroquinone (4%), and the other group
topical miconazole. Miconazol has antimelanotic properties and can be used as treatment for
melasma patients. The estimated number of subjects to be recruited and randomized for the
study is at least 30. The purpose of this study is determine if there is a difference in the
effectiveness of these two agents. Melasma Area and Severity Index (MASI) score will be
assessed at the beginning of the study and at weeks 4, 8, and 12. Photographs, colorimetry
and histological assessment will be also evaluated. Occurrence of adverse effects will also
be recorded.